Document is current
Any future updates will be listed below
-
Authors
Neiens, Vanessa https://orcid.org/0009-0007-8945-4883
Hansbauer, Eva-Maria https://orcid.org/0000-0003-4633-2644
Jaquin, Thomas J. https://orcid.org/0000-0002-4389-7554
Peper-Gabriel, Janet K.
Mahavadi, Poornima https://orcid.org/0000-0002-7580-4738
Snyder, Mark E. https://orcid.org/0000-0002-0092-9296
Grill, Maximilian J. https://orcid.org/0000-0003-1680-0259
Wurzenberger, Cornelia
Konitsiotis, Antonio
Estrada-Bernal, Adriana https://orcid.org/0000-0002-0555-2766
Heinig, Kristina
Fysikopoulos, Athanasios https://orcid.org/0000-0002-8081-0198
Schwenck, Nicolas
Grüner, Stefan https://orcid.org/0000-0002-3757-7677
Bartoschek, Denis
Mosebach, Theresia
Kerstan, Sandra
Wrennall, Joe
Richter, Marleen
Noda, Kentaro https://orcid.org/0000-0001-8921-1944
Hoetzenecker, Konrad
Burgess, Janette K. https://orcid.org/0000-0001-9868-9966
Tarran, Robert
Wurzenberger, Claudia
Wichmann, Karl-Robert https://orcid.org/0009-0002-2879-6613
Biehler, Jonas https://orcid.org/0000-0003-3032-1924
Müller, Kei W. https://orcid.org/0009-0004-0744-1623
Guenther, Andreas https://orcid.org/0000-0002-2187-0975
Eickelberg, Oliver https://orcid.org/0000-0001-7170-0360
Fitzgerald, Mary F.
Olwill, Shane A.
Matschiner, Gabriele
Pavlidou, Marina https://orcid.org/0000-0003-3753-0518
-
Funding
Funding for this research was provided by:
Bavarian Ministry of Economic Affairs, Regional Development and Energy https://www.stmwi.bayern.de/
- License Information
-
More Information
Article History
Received: 25 January 2024
Accepted: 20 March 2025
First Online: 5 April 2025
Competing interests
: M.P., V.N., E.M.H., Cl.W., T.J., S.G., G.M. are co-inventors of an international patent filed by Pieris Pharmaceuticals on the CCN2-targeting Anticalin protein described in this manuscript (WO2022214649A1). V.N., E.M.H, T.J., J.K.G., Co.W., A.K., K.H., A.F., N.S., S.G., D.B., T.M., S.K., M.R., Cl.W., M.F.F., S.A.O., G.M. and M.P. are or were employees of Pieris Pharmaceuticals and may hold stock interests in Pieris Pharmaceuticals. M.J.G, K.R.W, J.B. and K.W.M are employees and/or shareholders of Ebenbuild GmbH and co-inventors on a pending patent application. J.K.B receives research funds from Boehringer Ingelheim. The remaining authors declare no competing interests.
